Public health officials have once again emerged from their committee rooms to announce that, no, there will be no national screening programme for prostate cancer. The evidence is “uncertain”, the benefits “modest”, and the harms “not fully understood”. It’s a familiar refrain, delivered with impeccable calm, although it sits uneasily beside the far more generous standards applied to screening programmes that overwhelmingly benefit women.
Another Refusal on Prostate Screening – and Inequality
An empty NHS waiting room with rows of chairs and a wall clock
Once again, we find ourselves at the mercy of a familiar ritual. The UK National Screening Committee, the government’s own advisory body on screening, has completed its latest ‘Evidence Review’ on prostate cancer and emerged, after months of modelling, consultations and cautious phrasing, to say that there will be no national screening programme. Not this year, and not with this evidence. The report, written for ministers, NHS England and the wider public‑health establishment, concludes that population‑wide screening would still “do more harm than good”, and so the file is quietly closed, the recommendation passed upwards, and men are left exactly where they were before: waiting for a system that never quite seems to move on their behalf.
Not until the evidence is “clearer”, the harms “better understood”, and the benefits “more substantial”. One can almost hear the rustle of briefing papers and the gentle clearing of throats as the decision is delivered with the usual paternal calm: “We’ve looked at it very carefully, and we’re afraid the answer is still no.”
It’s, of course, true that the evidence is complicated. Prostate cancer is a tricky adversary. Some tumours are lethal, others so indolent they barely deserve the name. The PSA test, that much‑maligned little blood marker, can detect both with equal enthusiasm. The Swedish trials show that screening can indeed reduce prostate‑cancer deaths, but the absolute benefit is modest, you must screen roughly a thousand men to prevent a single death. Other trials, particularly in the US, have been less convincing, which gives the sceptics plenty to work with.
The Harms We Suddenly Care About
Then there are the harms. Overdiagnosis is real. Overtreatment is real. Men with low‑risk disease sometimes find themselves marched towards surgery or radiation they never needed, acquiring urinary or sexual side‑effects that can be far more life‑altering than the tumour ever would have been. The psychological burden of a cancer label, even a harmless one, isn’t trivial, and for older men, particularly those over 75, the evidence becomes even murkier. Many will die of something else long before a PSA test could save them.
All of this is true. All of it matters, although, one can’t help noticing that when the condition in question affects women, we seem remarkably adept at navigating complexity. We accept false positives. We accept overdiagnosis. We accept the emotional toll of a “possible cancer” that turns out to be nothing. We accept these things because we believe the benefits, even modest ones, justify the cost.
A Double Standard in Plain Sight
We don’t, for example, routinely tell women that screening for certain low‑mortality conditions is too messy, too uncertain, too fraught with potential harm. We don’t say, “Come back when the evidence is perfect.” We simply get on with it, because we have collectively decided that women’s health deserves that level of precaution.
So why, when the patient is male, do we suddenly become clinical purists?
The official answer is that the harms of PSA screening outweigh the benefits. The unofficial answer, the one no one says aloud, is that men’s health has never enjoyed the same cultural or political priority. Men are expected to muddle through, to be stoic, to present themselves to the GP only when something is falling off, and when they do ask for a national screening programme for the most common male cancer, they’re told, with impeccable courtesy, that the evidence is “not quite there”.
If Not Screening, Then What?
Perhaps it’s time to talk about equality.
If we are to deny men mass screening on the grounds that the mortality benefit is modest, then intellectual honesty demands we re‑examine every screening programme with similarly modest benefits, including those that overwhelmingly serve women. If, on the other hand, we accept that early detection, reassurance, and the prevention of late‑stage disease are valuable in their own right, then men deserve the same consideration.
What we can’t do is maintain a system in which women’s screening programmes are judged by one set of criteria and men’s by another. That isn’t evidence‑based medicine. It’s cultural habit dressed up as scientific rigour.
A British Story
No one is asking for extravagance. Men aren’t demanding a national programme to detect “stiff upper lip deficiency” or “chronic reluctance to see the doctor”. We’re asking for a fair hearing on a cancer that kills thousands of them every year. Men are collectively asking for the same precautionary principle that has long been extended to women. We’re asking, in short, for parity.
If the evidence truly isn’t strong enough, then fine, but let that rule be applied to everyone, not just men. Because when a system consistently withholds from one group what it freely offers another, it stops looking like caution and starts looking like state‑sponsored misandry: a structural, institutional disregard for men and their health.